Birdwatch Note
2024-10-01 01:02:35 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING
ワクチンは一般に効かないとの事ですが ワクチンの研究には有効性だけでも何万もの研究があり https://x.gd/aoJOI BCGも https://jamanetwork.com/journals/jama/article-abstract/366365 麻疹ワクチンも https://www.thelancet.com/journals/laninf/article/PIIS1473-30991930395-0/fulltext HPVワクチンも https://www.tandfonline.com/doi/full/10.1080/14760584.2023.2287135 ランダム化比較試験のメタ解析でその有効性は厳格なエビデンスとして示されています。 また最新のランダム化比較試験のメタアナリシスでもインフルエンザワクチンは対照群と比べ試験条件で一定の有効性が示されています。 https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(22)00061-X/fulltext
Written by F4D2E4CA66E08B99BDDE8328BBF4C2313B853B3595C8AC38600E463328C72D9D
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1840878498531197313
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1840920210813173778
- noteId - 1840920210813173778
- participantId -
- noteAuthorParticipantId - F4D2E4CA66E08B99BDDE8328BBF4C2313B853B3595C8AC38600E463328C72D9D Participant Details
- createdAtMillis - 1727744555558
- tweetId - 1840878498531197313
- classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
- believable -
- harmful -
- validationDifficulty -
- misleadingOther - 0
- misleadingFactualError - 1
- misleadingManipulatedMedia - 1
- misleadingOutdatedInformation - 0
- misleadingMissingImportantContext - 1
- misleadingUnverifiedClaimAsFact - 1
- misleadingSatire - 0
- notMisleadingOther - 0
- notMisleadingFactuallyCorrect - 0
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 0
- trustworthySources - 1
- summary
- ワクチンは一般に効かないとの事ですが ワクチンの研究には有効性だけでも何万もの研究があり https://x.gd/aoJOI BCGも https://jamanetwork.com/journals/jama/article-abstract/366365 麻疹ワクチンも https://www.thelancet.com/journals/laninf/article/PIIS1473-30991930395-0/fulltext HPVワクチンも https://www.tandfonline.com/doi/full/10.1080/14760584.2023.2287135 ランダム化比較試験のメタ解析でその有効性は厳格なエビデンスとして示されています。 また最新のランダム化比較試験のメタアナリシスでもインフルエンザワクチンは対照群と比べ試験条件で一定の有効性が示されています。 https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(22)00061-X/fulltext
Note Ratings
rated at | rated by | |
2024-10-02 12:55:55 -0500 | Rating Details | |
2024-10-02 12:46:29 -0500 | Rating Details | |
2024-10-01 10:09:56 -0500 | Rating Details | |
2024-10-01 06:49:11 -0500 | Rating Details | |
2024-10-01 04:11:35 -0500 | Rating Details | |
2024-10-01 03:54:10 -0500 | Rating Details | |
2024-10-01 03:30:43 -0500 | Rating Details | |
2024-10-01 03:14:38 -0500 | Rating Details | |
2024-10-01 03:09:06 -0500 | Rating Details | |
2024-10-01 02:09:32 -0500 | Rating Details | |
2024-10-01 01:06:00 -0500 | Rating Details | |
2024-10-01 01:00:33 -0500 | Rating Details | |
2024-10-01 00:33:21 -0500 | Rating Details | |
2024-10-01 00:31:05 -0500 | Rating Details | |
2024-09-30 23:46:22 -0500 | Rating Details | |
2024-09-30 23:38:30 -0500 | Rating Details | |
2024-09-30 23:27:04 -0500 | Rating Details | |
2024-09-30 23:09:59 -0500 | Rating Details | |
2024-09-30 23:03:03 -0500 | Rating Details | |
2024-09-30 22:59:50 -0500 | Rating Details | |
2024-09-30 22:59:20 -0500 | Rating Details | |
2024-09-30 22:41:47 -0500 | Rating Details | |
2024-09-30 22:33:39 -0500 | Rating Details | |
2024-09-30 22:26:37 -0500 | Rating Details | |
2024-09-30 22:21:47 -0500 | Rating Details | |
2024-09-30 21:47:40 -0500 | Rating Details | |
2024-09-30 21:47:35 -0500 | Rating Details | |
2024-09-30 21:47:09 -0500 | Rating Details | |
2024-09-30 21:46:26 -0500 | Rating Details | |
2024-09-30 21:39:06 -0500 | Rating Details | |
2024-09-30 21:38:59 -0500 | Rating Details | |
2024-09-30 21:35:51 -0500 | Rating Details | |
2024-09-30 21:33:47 -0500 | Rating Details | |
2024-09-30 21:32:09 -0500 | Rating Details | |
2024-09-30 21:08:59 -0500 | Rating Details | |
2024-09-30 21:07:46 -0500 | Rating Details | |
2024-09-30 20:54:59 -0500 | Rating Details | |
2024-09-30 20:54:53 -0500 | Rating Details | |
2024-09-30 20:47:33 -0500 | Rating Details | |
2024-09-30 20:46:10 -0500 | Rating Details | |
2024-09-30 20:37:33 -0500 | Rating Details | |
2024-09-30 20:37:11 -0500 | Rating Details | |
2024-09-30 20:33:51 -0500 | Rating Details | |
2024-09-30 20:29:50 -0500 | Rating Details | |
2024-09-30 20:28:52 -0500 | Rating Details | |
2024-09-30 20:27:03 -0500 | Rating Details | |
2024-09-30 20:22:19 -0500 | Rating Details | |
2024-09-30 20:20:05 -0500 | Rating Details | |
2024-09-30 20:18:36 -0500 | Rating Details | |
2024-09-30 20:16:17 -0500 | Rating Details | |
2024-10-04 08:41:43 -0500 | Rating Details | |
2024-10-04 02:28:35 -0500 | Rating Details | |
2024-10-03 02:16:27 -0500 | Rating Details | |
2024-10-01 06:08:43 -0500 | Rating Details | |
2024-10-01 04:50:03 -0500 | Rating Details | |
2024-10-01 04:28:40 -0500 | Rating Details | |
2024-09-30 22:57:55 -0500 | Rating Details | |
2024-09-30 22:53:53 -0500 | Rating Details | |
2024-09-30 22:52:41 -0500 | Rating Details | |
2024-09-30 22:50:14 -0500 | Rating Details | |
2024-09-30 22:09:47 -0500 | Rating Details | |
2024-09-30 21:58:01 -0500 | Rating Details | |
2024-09-30 21:15:59 -0500 | Rating Details | |
2024-09-30 21:11:17 -0500 | Rating Details | |
2024-09-30 20:39:28 -0500 | Rating Details | |
2024-09-30 20:32:32 -0500 | Rating Details | |
2024-09-30 20:20:23 -0500 | Rating Details | |
2024-09-30 20:14:26 -0500 | Rating Details | |
2024-09-30 20:07:49 -0500 | Rating Details | |
2024-09-30 20:06:12 -0500 | Rating Details | |
2024-10-01 04:49:27 -0500 | Rating Details | |
2024-10-01 04:17:56 -0500 | Rating Details | |
2024-10-01 03:16:01 -0500 | Rating Details | |
2024-10-01 00:13:39 -0500 | Rating Details | |
2024-09-30 23:51:16 -0500 | Rating Details | |
2024-09-30 21:39:30 -0500 | Rating Details | |
2024-09-30 21:19:21 -0500 | Rating Details | |
2024-09-30 21:17:15 -0500 | Rating Details | |
2024-09-30 23:11:23 -0500 | Rating Details | |
2024-09-30 21:46:15 -0500 | Rating Details |